Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
16
ABVC Quote, Financials, Valuation and Earnings
Last price:
$2.20
Seasonality move
:
-8.29%
Day range:
$2.03 - $2.09
52-week range:
$0.40 - $5.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
44.40x
P/B ratio:
4.11x
Volume:
52.1K
Avg. volume:
65.6K
1-year change:
320.62%
Market cap:
$49.6M
Revenue:
$509.6K
EPS (TTM):
-$0.22
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, ABVC BioPharma, Inc. has 890.2% upside to fair value with a price target of -- per share.
ABVC vs. S&P 500
-
Over the past 5 trading days, ABVC BioPharma, Inc. has underperformed the S&P 500 by -8.63% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ABVC BioPharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ABVC BioPharma, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter ABVC BioPharma, Inc. reported revenues of $796K.
Earnings Growth
-
ABVC BioPharma, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter ABVC BioPharma, Inc. reported earnings per share of -$0.05.
Enterprise value:
53.7M
EV / Invested capital:
3.14x
Price / LTM sales:
44.40x
EV / EBIT:
--
EV / Revenue:
67.27x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-29.49x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$327.8K
Return On Assets:
-29.85%
Net Income Margin (TTM):
-555.84%
Return On Equity:
-54.57%
Return On Invested Capital:
-40.7%
Operating Margin:
-146.78%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $739.3K | $509.8K | $797.9K | $389.3K | $796K | |
| Gross Profit | $290.6K | $39K | $327.8K | $282.6K | $699.9K | |
| Operating Income | -$9.4M | -$6M | -$4.5M | -$302.3K | -$1.2M | |
| EBITDA | -$9.4M | -$5.6M | -$4M | -$196K | -$1.1M | |
| Diluted EPS | -$3.53 | -$0.80 | -$0.22 | -$0.03 | -$0.05 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7.1M | $2.9M | $2.5M | $2.1M | $4.1M | |
| Total Assets | $14.8M | $12.1M | $17.3M | $14.5M | $21.2M | |
| Current Liabilities | $3.4M | $3.9M | $5.4M | $6.3M | $6.5M | |
| Total Liabilities | $4.8M | $4.8M | $7.5M | $6.5M | $6.7M | |
| Total Equity | $10.1M | $7.3M | $9.7M | $8M | $14.5M | |
| Total Debt | $1.3M | $880.2K | $2.2M | $142.2K | $164.1K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$4.2M | -$1.7M | -$1.8M | $60.2K | -$133.3K | |
| Cash From Investing | -$597.6K | -$302.6K | -$1.9M | $44.8K | -$1.3M | |
| Cash From Financing | $3.6M | $1.8M | $3.8M | -$81.4K | $1.1M | |
| Free Cash Flow | -$4.3M | -$1.7M | -$1.8M | $60.2K | -$138.7K | |
ABVC
Sector
Market Cap
$49.6M
$28.3M
Price % of 52-Week High
37.23%
51.3%
Dividend Yield
0%
0%
Shareholder Yield
-5.3%
-1.42%
1-Year Price Total Return
320.62%
-17.78%
Beta (5-Year)
0.243
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.12
200-day SMA
Sell
Level
$2.24
Bollinger Bands (100)
Sell
Level
2.53 - 3.09
Chaikin Money Flow
Sell
Level
-194.2M
20-day SMA
Sell
Level
$2.38
Relative Strength Index (RSI14)
Sell
Level
30.01
ADX Line
Sell
Level
31.22
Williams %R
Buy
Level
-89.7959
50-day SMA
Sell
Level
$2.70
MACD (12, 26)
Sell
Level
-0.20
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
358.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-14.8086)
Sell
CA Score
(Annual)
Level (-4.6707)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (9.4596)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.
Stock Forecast FAQ
In the current month, ABVC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ABVC average analyst price target in the past 3 months is --.
-
Where Will ABVC BioPharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that ABVC BioPharma, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About ABVC BioPharma, Inc.?
Analysts are divided on their view about ABVC BioPharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ABVC BioPharma, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is ABVC BioPharma, Inc.'s Price Target?
The price target for ABVC BioPharma, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ABVC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ABVC BioPharma, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ABVC?
You can purchase shares of ABVC BioPharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ABVC BioPharma, Inc. shares.
-
What Is The ABVC BioPharma, Inc. Share Price Today?
ABVC BioPharma, Inc. was last trading at $2.20 per share. This represents the most recent stock quote for ABVC BioPharma, Inc.. Yesterday, ABVC BioPharma, Inc. closed at $2.04 per share.
-
How To Buy ABVC BioPharma, Inc. Stock Online?
In order to purchase ABVC BioPharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ABVC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ABVC
Sector
P/E ratio
--
23.99x
PEG ratio
--
-0.01x
P/B ratio
4.11x
1.80x
Price / LTM sales
44.40x
1.59x
Growth Metrics
ABVC
Sector
Revenue growth
104.47%
4.62%
Earnings growth
-68.55%
10.71%
Revenue (5-year growth)
-6.2%
6.5%
Earnings forecast
--
-$0.20
Profitability
ABVC
Sector
Profitability FY 2024
$307.9K
$3.6M
Return on invested capital
-40.7%
-31.84%
Return on assets
-29.85%
-27.96%
Return on equity
-54.57%
-37.47%
Earnings Date
Last Earnings Date
Dec
20
Next Earnings Date
Dec
20
Estimated Next Earnings Date
Mar
21
Balance Sheet
ABVC
Sector
Total cash
$919.1K
$26.4M
Short term investments
$64.7K
$25.7M
Total assets
$7.5M
$78M
Long term debt
$164.1K
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
35
SMX alert for Dec 19
SMX (Security Matters) Plc [SMX] is up 11.91% over the past day.
Sell
36
INSP alert for Dec 19
Inspire Medical Systems, Inc. [INSP] is up 1.39% over the past day.
Sell
40
INSM alert for Dec 19
Insmed, Inc. [INSM] is up 4.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
